| Autor: |
Kostas Stamatopoulos, Anastasia Hadzidimitriou, Andreas M. Kaufmann, George Adonakis, Minas Paschopoulos, Ekaterini Chatzaki, Violetta Vaitsi, Athanasia Chronopoulou, Georgia Agelena, Vaia Piha, Theoni Truva, Despina Halatsi, Paraskevi Zempili, George Koukoulis, Ioannis Kalogiannidis, George Michail, George O. Decavalas, Theodoros Panoskaltsis, Efthimios Deligeoroglou, George Manidakis, Antonis Makrigiannakis, Emmanuel N. Kontomanolis, Vasilis Lymberis, Thomas Vrekoussis, Theodoros Stefos, Antonios Garas, Polyxeni Vanakara, Alexandros Daponte, Maria Ntoula, Ioannis Venizelos, Stamatia Aggelidou, Evangelia Katsiki, Alkmini Skenderi, Viktoria Moschaki, Theodoros Moysiadis, Anastasia Kitsou, Konstantinos Pasentsis, Evangelia Mouchtaropoulou, Athena Tsertanidou, Kimon Chatzistamatiou, Theodoros Agorastos |
| Rok vydání: |
2023 |
| DOI: |
10.1158/1940-6207.c.6547463.v1 |
| Popis: |
Self-sampling for human papillomavirus (HPV) testing is an alternative to physician sampling particularly for cervical cancer screening nonattenders. The GRECOSELF study is a nationwide observational cross-sectional study aiming to suggest a way to implement HPV-DNA testing in conjunction with self-sampling for cervical cancer screening in Greece, utilizing a midwifery network. Women residing in remote areas of Greece were approached by midwives, of a nationwide network, and were provided with a self-collection kit (dry swab) for cervicovaginal sampling and asked to answer a questionnaire about their cervical cancer screening history. Each sample was tested for high-risk (hr) HPV with the Cobas HPV test. HrHPV-Positive women were referred to undergo colposcopy and, if needed, treatment according to colposcopy/biopsy results. Between May 2016 and November 2018, 13,111 women were recruited. Of these, 12,787 women gave valid answers in the study questionnaire and had valid HPV-DNA results; hrHPV prevalence was 8.3%; high-grade cervical/vaginal disease or cancer prevalence was 0.6%. HrHPV positivity rate decreased with age from 20.7% for women aged 25–29 years to 5.1% for women aged 50–60 years. Positive predictive value for hrHPV testing and for HPV16/18 genotyping ranged from 5.0% to 11.6% and from 11.8% to 27.0%, respectively, in different age groups. Compliance to colposcopy referral rate ranged from 68.6% (for women 25–29) to 76.3% (for women 40–49). For women residing in remote areas of Greece, the detection of hrHPV DNA with the Cobas HPV test, on self-collected cervicovaginal samples using dry cotton swabs, which are provided by visiting midwives, is a promising method for cervical cancer secondary prevention. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
